<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019019</url>
  </required_header>
  <id_info>
    <org_study_id>950015</org_study_id>
    <secondary_id>95-C-0015</secondary_id>
    <secondary_id>NCI-CPB-334</secondary_id>
    <secondary_id>NCI-T94-0006N</secondary_id>
    <secondary_id>CDR0000063881</secondary_id>
    <nct_id>NCT00019019</nct_id>
    <nct_alias>NCT00001423</nct_alias>
  </id_info>
  <brief_title>Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas</brief_title>
  <official_title>A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH REFRACTORY CANCERS OR LYMPHOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining more than one drug may kill more cancer cells.

      PURPOSE: This phase I trial is studying the side effects and best dose of
      carboxyamidotriazole and paclitaxel in treating patients with advanced solid tumors or
      refractory lymphomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of paclitaxel when combined with
           carboxyamidotriazole in patients with advanced solid tumors or refractory lymphomas.

        -  Determine the pharmacokinetics and toxicities of this regimen in these patients.

        -  Identify diseases for which this combination appears active.

      OUTLINE: This is a dose escalation study.

      Patients receive oral carboxyamidotriazole (CAI) daily with paclitaxel IV over 3 hours on day
      8 and every 3 weeks thereafter. Course 1 is 28 days and all other subsequent courses are 21
      days. Treatment continues in the absence of disease progression or unacceptable toxicity.
      Patients who achieve complete response receive 2 additional courses of treatment.

      Sequential dose escalation of CAI is followed by sequential dose escalation of paclitaxel.
      Dose escalation in cohorts of 3 to 6 patients each continues until the maximum tolerated dose
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients
      experience dose limiting toxicity.

      PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1994</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Breast Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Lymphoma</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Small Intestine Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboxyamidotriazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically diagnosed solid tumor (i.e., breast and ovarian epithelial carcinomas)
             or lymphoma

               -  Slides reviewed at the NCI Laboratory of Pathology

          -  Failure on therapy of proven efficacy for the disease

               -  Prior therapy not required for the following metastatic diseases:

                    -  Melanoma

                    -  Non-small cell lung cancer

                    -  Renal cell carcinoma

          -  No brain metastases

               -  Primary brain tumors (such as glioblastoma multiforme) with stable neurologic
                  deficits allowed

          -  Measurable or evaluable disease required

               -  Demonstrated by physical exam or on radiograph within 2 weeks prior to initiation
                  of treatment OR

               -  Elevated PSA associated with prostate cancer

                    -  Other marker-only disease ineligible

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 18

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  At least 3 months

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hematocrit at least 27%

        Hepatic:

          -  Liver function tests no greater than 2 times upper limit of normal

          -  Bilirubin normal

          -  PT or PTT no greater than 1.25 times upper limit of normal

          -  Clotting parameters normal

          -  No concurrent anticoagulants other than 1 mg of warfarin per day for prophylaxis

        Renal:

          -  Creatinine no greater than 1.5 mg/dL OR

          -  Creatinine clearance at least 45 mL/min

          -  No kidney obstruction

        Cardiovascular:

          -  No cardiac conduction defect requiring antiarrhythmics

          -  No evidence of myocardial infarction or other myocardial damage within past 6 months

        Other:

          -  HIV negative

          -  No concurrent infection

          -  No guaiac-positive stool test

          -  No neuropathy greater than grade I (unless associated with fixed-deficit primary brain
             tumors)

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 2 months after study

        PRIOR CONCURRENT THERAPY:

          -  Recovery from prior therapy required

        Biologic therapy:

          -  At least 4 weeks since prior biologic therapy

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy (6 weeks since mitomycin, nitrosoureas, or
             carboplatin)

          -  No progression on carboxyamidotriazole or paclitaxel

          -  At least 6 months between treatment and relapse

        Endocrine therapy:

          -  At least 4 weeks since prior hormonal therapy

          -  No concurrent corticosteroids except as physiologic replacement

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy

        Surgery:

          -  Not specified

        Other:

          -  At least 1 week since prior therapeutic antibiotics

          -  Concurrent prophylactic antibiotics allowed except imidazole antifungals (e.g.,
             ketoconazole, fluconazole)

          -  No concurrent calcium channel blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia Kwitkowski, MS, RN, CS, CRNP</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Medical Oncology Clinical Research Unit</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. Clin Cancer Res. 2001 Jun;7(6):1600-9.</citation>
    <PMID>11410496</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult craniopharyngioma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult meningioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult pineocytoma</keyword>
  <keyword>adult pineoblastoma</keyword>
  <keyword>adult meningeal hemangiopericytoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>adult choroid plexus tumor</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult grade III meningioma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboxyamido-triazole</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

